正在加载中

【科技前瞻】JHEP Reports:人脐带间充质干细胞来源外泌体为治疗非酒精性脂肪肝提供新思路

2026-04-16 16:21:06 博鳌干细胞

非酒精性脂肪肝(NAFLD)包含单纯的脂肪变性到非酒精性脂肪肝炎,并可能进一步发展导致纤维化、肝硬化,甚至是肝细胞癌。全球约24%的人口受到NAFLD的影响,成为公共卫生系统的一项重要问题。NAFLD的肝细胞损伤、炎症和肝脏脂肪变性涉及肝脏脂肪酸氧化减少和脂肪酸合成增加,因此探索有效调节脂质代谢的治疗方法,将有助于预防肝脏脂肪变性并发展为慢性肝病。然而,目前尚未有批准上市的NAFLD的治疗药物,需求仍然十分迫切。间充质干细胞来源外泌体因其具有与来源细胞类似的损伤修复和炎症调节等生物功能,被认为是一种潜在的治疗策略。近日,研究人员报道了人脐带间充质干细胞来源外泌体(MSC-ex)在脂肪变性的作用和潜在机制。相关研究结果发表在JHEP Reports上。

乐城医疗先行区

研究人员构建了油酸处理的肝细胞和高脂饮食(HFD)诱导的NAFLD小鼠,并观察MSC-ex的作用。结果发现,MSC-ex促进油酸处理的肝细胞和HFD诱导的NAFLD小鼠的脂肪酸氧化并减少脂肪形成。非靶向脂质组学和转录组分析表明,MSC-ex对脂质积累的影响与AMP活化蛋白激酶的磷酸化呈正相关。进一步机制研究发现,MSC-ex携带的CAMKK1通过AMPK介导的PPARα/CPT-1A和SREBP-1C/FASn信号在肝细胞中发挥调解脂质代谢的重要作用。综上,该研究揭示了基于MSC-ex治疗预防NAFLD的新机制,为开发基于间充质干细胞来源外泌体治疗NAFLD提供了证据。

推荐阅读原文:

Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis.

Background & aims: Non-alcoholic fatty liver disease (NAFLD) affects nearly a quarter of the population with no approved pharmacological therapy. Liver steatosis is a primary characteristic of NAFLD. Recent studies suggest that human umbilical cord mesenchymal stem cell-derived exosomes (MSC-ex) may provide a promising strategy for treating liver injury; however, the role and underlying mechanisms of MSC-ex in steatosis are not fully understood.

Methods: Oleic-palmitic acid-treated hepatic cells and high-fat diet (HFD)-induced NAFLD mice were established to observe the effect of MSC-ex. Using non-targeted lipidomics and transcriptome analyses, we analysed the gene pathways positively correlated with MSC-ex. Mass spectrometry and gene knockdown/overexpression analyses were performed to evaluate the effect of calcium/calmodulin-dependent protein kinase 1 (CAMKK1) transferred by MSC-ex on lipid homoeostasis regulation.

Results: Here, we demonstrate that MSC-ex promote fatty acid oxidation and reduce lipogenesis in oleic-palmitic acid-treated hepatic cells and HFD-induced NAFLD mice. Non-targeted lipidomics and transcriptome analyses suggested that the effect of MSC-ex on lipid accumulation positively correlated with the phosphorylation of AMP-activated protein kinase. Furthermore, mass spectrometry and gene knockdown/overexpression analyses revealed that MSC-ex-transferred CAMKK1 is responsible for ameliorating lipid accumulation in an AMP-activated protein kinase-dependent manner, which subsequently inhibits SREBP-1C-mediated fatty acid synthesis and enhances peroxisome proliferator-activated receptor alpha (PPARα)-mediated fatty acid oxidation.

Conclusions: MSC-ex may prevent HFD-induced NAFLD via CAMKK1-mediated lipid homoeostasis regulation.

Impact and implications: NAFLD includes many conditions, from simple steatosis to non-alcoholic steatohepatitis, which can lead to fibrosis, cirrhosis, and even hepatocellular carcinoma. So far, there is no approved drug for treating liver steatosis of NAFLD. Thus, better therapies are needed to regulate lipid metabolism and prevent the progression from liver steatosis to chronic liver disease. By using a combination of non-targeted lipidomic and transcriptome analyses, we revealed that human umbilical cord mesenchymal stem cell-derived exosomes (MSC-ex) effectively reduced lipid deposition and improved liver function from HFD-induced liver steatosis. Our study highlights the importance of exosomal CAMKK1 from MSC-ex in mediating lipid metabolism regulation via AMPK-mediated PPARα/CPT-1A and SREBP-1C/fatty acid synthase signalling in hepatocytes. These findings are significant in elucidating novel mechanisms related to MSC-ex-based therapies for preventing NAFLD.

来源:中国干细胞集团海南干细胞医院


4001-650-660

周一至周日 9:00-20:00(仅收市话费)

留言